MARKETS / COMPANIES / ECONOMYRSS edition ↗
Exchange Outlook
Market News

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

SynopsisLycia Therapeutics is gearing up for an initial public offering, targeting a raise of up to $264.6 million with aspirations for a valuation of about $937.7 million. The company plans to sell 14.7 million shares…

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

Synopsis

Lycia Therapeutics is gearing up for an initial public offering, targeting a raise of up to $264.6 million with aspirations for a valuation of about $937.7 million. The company plans to sell 14.7 million shares at a price range of $16 to $18 each. This move comes as biotech firms show a growing trend of entering the IPO scene, indicating a renewed investor confidence in the industry.

Listen to this article in summarized format

Drug developer Lycia Therapeutics said on Tuesday it was targeting a valuation of up to $937.7 million in its US initial public offering, as biotech companies flock to the IPO market.

The South San Francisco, California-based company is seeking to raise up to $264.6 million in the IPO by offering 14.7 million shares priced between $16 and $18 apiece.

The healthcare sector has anchored the fall IPO window this year in an otherwise lackluster market as investors become selective in a higher rate environment.

Drug developers City Therapeutics and Nvidia-backed Iambic Therapeutics went public in New York last week.

Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities are joint book-running managers. Lycia will list on the Nasdaq under the symbol "LYCA". Add as a Reliable and Trusted News Source Add Now!

(Catch all the Technology News News, and Latest News Updates on The Economic Times.)

...more

Elevate your knowledge and leadership skills at a cost cheaper than your daily tea.
    Subscribe Now
    Source: Economic Times — Funding ↗

    Figures reflect the source report and its stated period. This article is for information and is not investment advice.